Axonics, Inc. (AXNX) Misses Q3 EPS by 11c, Beats on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Axonics, Inc. (AXNX) Misses Q3 EPS by 11c, Beats on Revenue

Axonics Reports Third Quarter 2024 Financial Results

November 7, 2024 4:01 PM EST

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024.

Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year, said Raymond W. Cohen, chief executive officer. Revenue growth for both sacral neuromodulation and Bulkamid® was driven by higher utilization at existing customers and the onboarding of new accounts.

Mr. Cohen continued, Our commitment to innovation, quality,... More